1,080 results on '"Park, Young Nyun"'
Search Results
2. Albumin, filamin-A and cytokeratin 19 help distinguish intrahepatic cholangiocarcinoma from extrahepatic adenocarcinoma
3. Comparison of imaging findings of macrotrabecular-massive hepatocellular carcinoma using CT and gadoxetic acid–enhanced MRI
4. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study
5. Differentiation between hepatic angiomyolipoma and hepatocellular carcinoma in individuals who are not at-risk for hepatocellular carcinoma
6. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)
7. MRI features of histologic subtypes of hepatocellular carcinoma: correlation with histologic, genetic, and molecular biologic classification
8. SAT-522 Comparison of magnetic resonance imaging (MRI) characteristics of hepatocellular carcinoma (HCC) based underlying liver disease
9. THU-446 VETC predicts benefit of anti-angiogenic drugs in advanced HCC
10. Noninvasive surrogates are poor predictors of liver fibrosis in patients with Fontan circulation
11. SEPT9 Expression in Hepatic Nodules: An Immunohistochemical Study of Hepatocellular Neoplasm and Metastasis
12. cHCC‐CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation
13. Prognostic Significance of the Macrotrabecular-Massive Hepatocellular Carcinoma Subtype in Liver Transplantation: A Retrospective Cohort Study
14. Clinical and survival outcomes after hepatectomy in patients with non-alcoholic fatty liver and hepatitis B-related hepatocellular carcinoma
15. Comparison of the current guidelines for diagnosing hepatocellular carcinoma using gadoxetic acid–enhanced magnetic resonance imaging
16. YAP inactivation in estrogen receptor alpha-positive hepatocellular carcinoma with less aggressive behavior
17. Subcentimeter hepatocellular carcinoma in treatment-naïve patients: noninvasive diagnostic criteria and tumor staging on gadoxetic acid–enhanced MRI
18. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study
19. Glioblastomas harboring gene fusions detected by next-generation sequencing
20. Evidence for continuity of interstitial spaces across tissue and organ boundaries in humans
21. Identification of prognostic biomarker in predicting hepatocarcinogenesis from cirrhotic liver using protein and gene signatures
22. Gross type of hepatocellular carcinoma reflects the tumor hypoxia, fibrosis, and stemness-related marker expression
23. Eukaryotic translation initiation factor 6 overexpression plays a major role in the translational control of gallbladder cancer
24. Intraductal papillary neoplasm of the bile duct: Assessment of invasive carcinoma and long-term outcomes using MRI
25. Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival
26. Subclassification of Microscopic Vascular Invasion in Hepatocellular Carcinoma
27. Response to Comment on “Subclassification of Microscopic Vascular Invasion in Hepatocellular Carcinoma”
28. ERS: A simple scoring system to predict early recurrence after surgical resection for hepatocellular carcinoma
29. Response to Comment on “Subclassification of Microscopic Vascular Invasion in Hepatocellular Carcinoma”
30. Subclassification of Microscopic Vascular Invasion in Hepatocellular Carcinoma
31. Optimal lexicon of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of hepatocellular carcinoma modified from LI-RADS
32. A proposal of imaging classification of intrahepatic mass-forming cholangiocarcinoma into ductal and parenchymal types: clinicopathologic significance
33. Deep learning predicts sensitivity to atezolizumab-bevacizumab from digital slides of hepatocellular carcinoma
34. ARID1A Mutation from Targeted NGS Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer
35. Steatotic hepatocellular carcinoma: Association of MRI findings to underlying liver disease and clinicopathological characteristics
36. Supplementary Figures 1-6 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
37. Supplementary Figure Legend from RASSF1A-Mediated Regulation of AREG via the Hippo Pathway in Hepatocellular Carcinoma
38. Supplementary Table 5 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
39. Supplementary Figure 1 from RASSF1A-Mediated Regulation of AREG via the Hippo Pathway in Hepatocellular Carcinoma
40. Supplementary Methods and Supplementary Figure and Table Legends from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
41. Supplementary Table 4 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
42. Supplementary Table 2 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
43. Supplementary Table 1 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
44. Data from RASSF1A-Mediated Regulation of AREG via the Hippo Pathway in Hepatocellular Carcinoma
45. Supplementary Tables 1 - 2 from RASSF1A-Mediated Regulation of AREG via the Hippo Pathway in Hepatocellular Carcinoma
46. Supplementary Table 3 from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
47. Supplementary Figure 2 from RASSF1A-Mediated Regulation of AREG via the Hippo Pathway in Hepatocellular Carcinoma
48. Data from Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
49. New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors
50. CYP1A2 is a predictor of HCC recurrence in HCV-related chronic liver disease: A retrospective multicentric validation study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.